Natco Pharma Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Natco Pharma Ltd has surpassed key resistance levels, indicating bullish momentum supported by strong volumes. Analysts recommend buying with an expected upside of ₹1,150-1,180.

Natco Pharma Shows Strong Bullish Momentum - 08 Apr, 2026

Natco Pharma's stock surged over 5%, breaking a 13-month resistance. The company launched an affordable Semaglutide Injection and plans to demerge its agrochemicals business, enhancing its market position. With a low PE ratio and strong technical indicators, Natco shows promising growth potential.

Natco Pharma Breaks Resistance, Launches Affordable GLP-1 Therapy - 07 Apr, 2026

Natco Pharma has launched its generic Semaglutide injection in India at ₹1,290, significantly undercutting competitors. This move aims to improve accessibility for diabetes patients and support long-term compliance.

Natco Pharma Launches Affordable Semaglutide Injection - 20 Mar, 2026

Natco Pharma's board will discuss a scheme to demerge its agrochemicals division into Natco Crop Health Sciences Ltd on March 24, 2026. The move aims to enhance operational efficiency and strategic focus.

Natco Pharma Plans Agrochemicals Division Demerger - 18 Mar, 2026

Natco Pharma shares surged 5% to ₹1,047.65, nearing a 52-week high, driven by the launch of Pomalidomide Capsules in the US and upcoming Semaglutide launch in India. Despite recent earnings challenges, the company maintains a positive outlook with strong revenue guidance.

Natco Pharma Stock Rallies on Positive Developments - 10 Mar, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 3 months, NATCOPHARM stock has moved up by 25.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 1.60% to 1.72% in Mar 2026 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Foreign Institutions have increased holdings from 15.16% to 17.37% in Mar 2026 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 1 year, NATCOPHARM has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 3 years, Lupin Ltd has given 251.8% return, outperforming this stock by 162.7%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Revenue is down for the last 2 quarters, 1.46K Cr → 705.4 Cr (in ₹), with an average decrease of 51.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Netprofit is down for the last 2 quarters, 518.4 Cr → 151.5 Cr (in ₹), with an average decrease of 70.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Promoters have decreased holdings from 49.48% to 49.42% in Mar 2026 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Retail Investor have decreased holdings from 29.96% to 27.75% in Mar 2026 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

BSE 500

Nifty 500

Nifty Smallcap 50

Nifty MidSmallcap 400

S&P BSE 250 SmallCap

S&P BSE 400 MidSmallCap

Nifty Small 100

BSE Healthcare

Nifty Smallcap 250

Tata Value Fund Direct Plan Growth

Sundaram Small Cap Fund - Direct Plan - Growth Option

Tata Small Cap Fund Direct Growth

JioBlackRock Flexi Cap Fund Direct Growth

Nippon India Nifty Smallcap 250 Index Fund Dir Gr

Natco Pharma Ltd’s net profit jumped 13.91% since last year same period to ₹151.50Cr in the Q3 2025-2026. On a quarterly growth basis, Natco Pharma Ltd has generated -70.78% fall in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.49	Bearish
CCI (20)	-346.31	Bullish
RSI (14)	54.61	Neutral
Momentum (10)	-0.45	Bearish
ADI (14)	27.66	Bearish
Ultimate Oscillator (7,14,28)	66.48	Neutral

Name	Value	Action
SMA (20)	1092.17	Bearish
EMA (20)	1091.39	Bullish
VWMA (20)	1091.74	Bearish
SMA (50)	1089.29	Bullish
EMA (50)	1089.84	Bullish
SMA (200)	1083.76	Bullish
EMA (200)	1085.51	Bullish
KAMA (200)	1090.05	Bullish
DEMA (200)	1088.28	Bullish

Natco Pharma Ltd (NATCOPHARM)

Summary

Overall

Oscillators

Moving Averages